Skip to main content
. 2023 May 25;9(5):mgen001020. doi: 10.1099/mgen.0.001020

Table 3.

Antimicrobial susceptibility of S. aureus isolates

N tested=number of isolates tested for any given antibiotic. Results are expressed as the percentage of tested isolates that are non-susceptible (% Intermediate + % Resistance, %I+R). ERY, erythromycin; CL, clindamycin; GEN, gentamicin; SXT, trimethoprim-sulfamethoxazole; RIF, rifampin; CIP, ciprofloxacin; LVX, levofloxacin; MNO, minocycline.

Antibiotic

S. aureus

MRSA, n=182

MSSA, n=261

P-value

MRSA-HA n=78

MRSA-CA, n=96

P-value

MSSA-HA, n=126

MSSA-CA, n=123

P-value

N tested

N

(%I+R)

N tested

N

(%I+R)

N tested

N

(%I+R)

N tested

N

(%I+R)

N tested

N

(%I+R)

N tested

N

(%I+R)

N tested

N

(%I+R)

ERY

441

131 (29.7 %)

180

54 (30 %)

261

77 (29.5 %)

0.91

78

36 (46.2 %)

94

16 (17.0 %)

5.10E-05

126

34 (27.0 %)

123

37 (30.0 %)

0.67

CLI

443

119 (26.9 %)

182

43 (23.6 %)

261

76 (29.1 %)

0.23

78

30 (38.5 %)

96

12 (12.5 %)

8.11E-05

126

34 (27.0 %)

123

36 (29.3 %)

0.77

GEN

431

69 (16.0 %)

178

49 (27.5 %)

253

20 (7.9 %)

9.13E-08

77

26 (33.8 %)

93

23 (24.7 %)

0.23

122

9 (7.4 %)

119

9 (7.6 %)

1

SXT

437

5 (1.1 %)

179

5 (2.8 %)

258

0 (0.0 %)

0.01

78

4 (5.1 %)

93

1 (1.1 %)

0.17

124

0 (0.0 %)

122

0 (0.0 %)

1

RIF

428

11 (2.6 %)

172

9 (5.2 %)

256

2(0.8 %)

0.008

77

5 (6.5 %)

87

4 (4.6 %)

0.73

124

1 (0.8 %)

120

1 (0.8 %)

1

CIP

383

46 (12.0 %)

158

29 (18.4 %)

225

17 (7.5 %)

0.002

68

19 (27.9 %)

88

10 (11.4 %)

0.012

113

6 (5.3 %)

106

11 (10.3 %)

0.2

LVX

330

28 (8.5 %)

131

23 (17.5 %)

199

5 (2.5 %)

2.38E-06

60

13 (21.7 %)

64

7 (10.9 %)

0.14

94

2 (2.1 %)

94

3 (3.2 %)

1

MNO

364

2 (0.5 %)

145

1 (0.7 %)

219

1 (0.4 %)

1

67

1 (1.5 %)

76

0 (0.0 %)

0.46

112

1 (0.9 %)

101

0 (0.0 %)

1